Dr. Julio Fernandez career started at the University of Santiago de Compostela, Spain where he received a B.S. in Biology and a PhD. in molecular biology. His interests in the application of computational methods led of a MSc. in Bioinformatics from the Chalmers University of Technology, Sweden. In 2005, Dr. Fernandez joined the Wellcome Trust Sanger Institute, where he was part of the EnsEMBL genome annotation team, focusing on the development of pipelines for the genome annotation of major vertebrate genomes (Human, Mouse and Rat). After one year collaboration at the European Bioinformatics Institute, Dr. Fernandez joined Pfizer La Jolla in 2011. At Pfizer he contributed to the development of OASIS, a cancer genomics analytical platform and participated in the implementation of different solutions to integrate and analyze cancer related data. Since October 2017, he has lead multiple genomics and big data projects at Monoceros Biosystems.
Dr. Fernandez has considerable expertise in data analysis applied to various stages of drug discovery including early discovery, pre-clinical and clinical development. He has published in top ranked journals including Nature Genetics, Nature Methods, Nucleic Acids Research, Genome Research, and Bioinformatics.